Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT03157830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03157830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
Lead sponsor
Providence Health & Services
Phase
Observational
Overall status
Completed
Start date
June 1, 2017
Completion date
June 6, 2022
Enrollment
43 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis